These findings indicated that the LL of KAZ resulted in a lower rate of degradation of high‐ and low‐molecular‐weight myofibrillar proteins than that of BC did, possibly due to differences in the levels of stimulated μ‐calpain and cathepsin B (Lomiwes et al. 2014). This evidence concerns the gene KAZN and breast cancer.